Canadian Neuroscience Research luncheon in Parliament CAN Connection January 2017 CAN 2016 election results Royal Society of Canada nominations Montreal 2017 Matthew Hill is the 2016 CAN Young Investigator CAN Advocacy contest winners impact of neurological disorders in Canada

 

CAN-ACN news

University of British Columbia Researchers Have Found A Way To Block The High of Cocaine

“If you got that lose, you want to kick them blues, cocaine
When your day is done, and you want to ride on cocaine
She don’t lie, she don’t lie, she don’t lie
Cocaine.”

-Eric Clapton

Despite its illegal status, cocaine remains one of the staples of social drug use. The stimulating effect of the chemical has been glamorized in modern-day culture and continues to be lauded as a means to artificially keep the mind active. Yet, as anyone who has tried this high can tell, the side effects are far less delightful. They include memory loss, increase heart rate, insomnia, and almost instantaneous addiction.

Discovering The Genetic Cause For Obsessive-Compulsive Disorder

Of all psychiatric conditions, obsessive-compulsive disorder, or OCD as it’s more commonly known, is perhaps the most widely known and also, misunderstood. Colloquially, this term is used to describe anyone with a penchant for a obsessive nature. Yet, this ailment, which only affects about 2% of the population, is quite difficult to both diagnose and manage.

Neuroscience news

Largest international study of its kind finds new schizophrenia risk genes

Stephen Scherer

Stephen Scherer

Results of the International Psychiatric Genomics Consortium unveiled

TORONTO – Canadian and international scientists have uncovered six new schizophrenia risk genes in the largest study of its kind. The results of the international Psychiatric Genomics Consortium CNV working group are published in the Nov. 21 advance online edition of Nature Genetics, and further support the important role genes play in susceptibility to schizophrenia, and may be helpful in early diagnosis.

UBC scientists create a mouse that resists cocaine’s lure

Shernaz BamjiScientists at the University of British Columbia have genetically engineered a mouse that does not become addicted to cocaine, adding to the evidence that habitual drug use is more a matter of genetics and biochemistry than just poor judgment.

The mice they created had higher levels of a protein called cadherin, which helps bind cells together. In the brain, cadherin helps strengthen synapses between neurons – the gaps that electrical impulses must traverse to bring about any action or function controlled by the brain, whether it’s breathing, walking, learning a new task or recalling a memory.

An eye-catching result

Brian White

Brian White

Research determines how the brain recognizes what’s important at first glance.

Researchers at the Centre for Neuroscience Studies (CNS) at Queen’s University have discovered that a region of the brain – the superior colliculus – contains a mechanism responsible for interpreting how visual input from a scene determines where we look. This mechanism, known as a visual salience map, allows the brain to quickly identify and act on the most important information in the visual field, and is a basic mechanism for our everyday vision.

Lack of joy from music linked to brain disconnection

Dr. Robert Zatorre

Dr. Robert Zatorre

Have you ever met someone who just wasn’t into music? They may have a condition called specific musical anhedonia, which affects three-to-five per cent of the population.

Researchers at the University of Barcelona and the Montreal Neurological Institute and Hospital of McGill University have discovered that people with this condition showed reduced functional connectivity between cortical regions responsible for processing sound and subcortical regions related to reward.

Breakthrough in MS treatment

Amit Bar-Or

Amit Bar-Or

Drug shown to reduce new attacks/symptom progression in some patients

In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary progressive MS.

Three studies conducted by an international team of researchers, which included Amit Bar-Or and Douglas Arnold from the Montreal Neurological Institute and Hospital of McGill University, have discovered that ocrelizumab can significantly reduce new attacks in patients with relapsing MS, as well as slow the progression of symptoms caused by primary progressive MS.